- Home
- ASPI vs ATXS Comparison
ASPI vs ATXS Comparison
Compare ASPI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- ATXS
- Stock Information
- Founded
- ASPI 2021
- ATXS 2008
- Country
- ASPI United States
- ATXS United States
- Employees
- ASPI N/A
- ATXS N/A
- Industry
- ASPI Major Chemicals
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- ATXS Health Care
- Exchange
- ASPI Nasdaq
- ATXS Nasdaq
- Market Cap
- ASPI 476.8M
- ATXS 401.2M
- IPO Year
- ASPI 2022
- ATXS 2015
- Fundamental
- Price
- ASPI $4.77
- ATXS $6.81
- Analyst Decision
- ASPI Strong Buy
- ATXS Strong Buy
- Analyst Count
- ASPI 2
- ATXS 6
- Target Price
- ASPI $4.50
- ATXS $25.67
- AVG Volume (30 Days)
- ASPI 2.2M
- ATXS 244.9K
- Earning Date
- ASPI 04-09-2025
- ATXS 03-03-2025
- Dividend Yield
- ASPI N/A
- ATXS N/A
- EPS Growth
- ASPI N/A
- ATXS N/A
- EPS
- ASPI N/A
- ATXS N/A
- Revenue
- ASPI $3,383,374.00
- ATXS N/A
- Revenue This Year
- ASPI $865.76
- ATXS N/A
- Revenue Next Year
- ASPI $700.00
- ATXS N/A
- P/E Ratio
- ASPI N/A
- ATXS N/A
- Revenue Growth
- ASPI N/A
- ATXS N/A
- 52 Week Low
- ASPI $1.86
- ATXS $6.64
- 52 Week High
- ASPI $9.33
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- ASPI 40.96
- ATXS 31.94
- Support Level
- ASPI $4.57
- ATXS $6.77
- Resistance Level
- ASPI $5.79
- ATXS $7.30
- Average True Range (ATR)
- ASPI 0.53
- ATXS 0.30
- MACD
- ASPI -0.16
- ATXS 0.02
- Stochastic Oscillator
- ASPI 8.26
- ATXS 14.66
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.